These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 2474882)

  • 41. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
    Roehrborn CG; McVary KT; Elion-Mboussa A; Viktrup L
    J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The role of LH-RH analogue in benign prostatic hyperplasia].
    Ferretti S; Salsi P; Arena F; Peracchia G; Cortellini P
    Acta Biomed Ateneo Parmense; 1993; 64(1-2):23-7. PubMed ID: 7518631
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Unusual side effect from a luteinizing hormone-releasing hormone agonist, leuprorelin, in the treatment of prostate cancer: a case report.
    Chang JI; Bucci J
    J Med Case Rep; 2016 Nov; 10(1):323. PubMed ID: 27836000
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Hormonal and clinical efficacy of (D-Leu6)-des Gly-NH2(10)-LH.RH ethylamide against prostatic cancer].
    Imai K; Kumasaka F; Kobayashi M; Suzuki T; Takahashi O; Yamanaka H
    Hinyokika Kiyo; 1985 Dec; 31(12):2302-6. PubMed ID: 2938456
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.
    Tolis G; Ackman D; Stellos A; Mehta A; Labrie F; Fazekas AT; Comaru-Schally AM; Schally AV
    Proc Natl Acad Sci U S A; 1982 Mar; 79(5):1658-62. PubMed ID: 6461861
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Consultation patterns in a community survey of men with benign prostatic hyperplasia.
    Simpson RJ; Lee RJ; Garraway WM; King D; McIntosh I
    Br J Gen Pract; 1994 Nov; 44(388):499-502. PubMed ID: 7538316
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
    Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
    J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.
    McConnell JD; Bruskewitz R; Walsh P; Andriole G; Lieber M; Holtgrewe HL; Albertsen P; Roehrborn CG; Nickel JC; Wang DZ; Taylor AM; Waldstreicher J
    N Engl J Med; 1998 Feb; 338(9):557-63. PubMed ID: 9475762
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells.
    Minaretzis D; Alper MM; Oskowitz SP; Lobel SM; Mortola JF; Pavlou SN
    Am J Obstet Gynecol; 1995 May; 172(5):1518-25. PubMed ID: 7755066
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia.
    Rick FG; Schally AV; Block NL; Abi-Chaker A; Krishan A; Szalontay L
    Prostate; 2013 Jun; 73(8):873-83. PubMed ID: 23280565
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of combination therapy with a luteinizing hormone-releasing hormone agonist and chlormadinone acetate on rat prostate weight and plasma testosterone levels.
    Gotanda K; Shinbo A; Okada M; Nakano Y; Kobayashi H; Sasaki T; Hagiwara M; Akaza H
    Prostate Cancer Prostatic Dis; 2003; 6(1):66-72. PubMed ID: 12664069
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Luteinizing hormone (LH)-releasing hormone agonist reduces serum adrenal androgen levels in prostate cancer patients: implications for the effect of LH on the adrenal glands.
    Nishii M; Nomura M; Sekine Y; Koike H; Matsui H; Shibata Y; Ito K; Oyama T; Suzuki K
    J Androl; 2012; 33(6):1233-8. PubMed ID: 22492843
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prostatic enlargement, symptomatology and pressure/flow evaluation: interrelations in patients with symptomatic BPH.
    Poulsen AL; Schou J; Puggaard L; Torp-Pedersen S; Nordling J
    Scand J Urol Nephrol Suppl; 1994; 157():67-73. PubMed ID: 7524143
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Urodynamic effects of transrectal intraprostatic Ona botulinum toxin A injections for symptomatic benign prostatic hyperplasia.
    de Kort LM; Kok ET; Jonges TN; Rosier PF; Bosch JL
    Urology; 2012 Oct; 80(4):889-93. PubMed ID: 22854138
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Skin reaction induced by subcutaneous injection of LH-RH analogue].
    Segawa N; Nishida T; Hamada S; Azuma H; Katsuoka Y; Nozaki K; Tsuji M
    Hinyokika Kiyo; 2007 Oct; 53(10):695-8. PubMed ID: 18018584
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prostate-specific antigen and transition zone index - powerful predictors for acute urinary retention in men with benign prostatic hyperplasia.
    Milonas D; Trumbeckas D
    Medicina (Kaunas); 2003; 39(11):1071-7. PubMed ID: 14646460
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intraprostatic botulinum toxin type a injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement. Effect on prostate volume and micturition resumption.
    Silva J; Silva C; Saraiva L; Silva A; Pinto R; Dinis P; Cruz F
    Eur Urol; 2008 Jan; 53(1):153-9. PubMed ID: 17825981
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Acute retention of urine due to benign prostatic obstruction treated with alpha-adrenergic blockers.
    Reuther K; Aagaard J
    Urol Int; 1984; 39(2):114-5. PubMed ID: 6202036
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia.
    Homma Y; Gotoh M; Kawauchi A; Kojima Y; Masumori N; Nagai A; Saitoh T; Sakai H; Takahashi S; Ukimura O; Yamanishi T; Yokoyama O; Yoshida M; Maeda K
    Int J Urol; 2017 Oct; 24(10):716-729. PubMed ID: 28748576
    [TBL] [Abstract][Full Text] [Related]  

  • 60. One-month release injectable microcapsules of a luteinizing hormone-releasing hormone agonist (leuprolide acetate) for treating experimental endometriosis in rats.
    Okada H; Heya T; Ogawa Y; Shimamoto T
    J Pharmacol Exp Ther; 1988 Feb; 244(2):744-50. PubMed ID: 3126294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.